Nephrada · IGAN · Germany · Community nephrologist · captured by Dr. Anna Becker on 14 Apr 2026 · reviewed by Dr. Sophie Laurent on 16 Apr 2026
Verbatim as captured; never edited
Community nephrologist at Universitätsklinikum Heidelberg raised treatment burden and fatigue during a investigator meeting. They indicated this influences their current prescribing approach.
Human-approved by Dr. Sophie Laurent on 16 Apr 2026
Treatment burden and fatigue: interest in collaboration reported by community nephrologist (DE).
helixor-private-llm-2026.05 · generated 14 Apr 2026, 10:00 UTC
AI summary
Treatment burden and fatigue raised by community nephrologist; suggest routing to Market Access.
Source spans used by the model
Community nephrologist at Universitätsklinikum Heidelberg raised treatment burden and fatigue during a investigator meeting. They indicated this influences their current prescribing approach.
| Field | AI suggestion | Final (human-approved) |
|---|---|---|
| Category | Access and reimbursement | Access and reimbursement |
| Function | Market Access | Market Access |
| Priority | Medium | Medium |
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 3 | 20% | 12.0 |
| Strategic alignment | 1 | 20% | 4.0 |
| Scientific importance | 2 | 15% | 6.0 |
| Urgency | 3 | 15% | 9.0 |
| Novelty | 4 | 10% | 8.0 |
| Actionability | 4 | 10% | 8.0 |
| Confidence | 2 | 5% | 2.0 |
| Breadth of occurrence | 4 | 5% | 4.0 |
| Total | Medium 53 | ||
No audit events in sample data
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
12 Apr 2026 · Dr. Benedikt Vogel, Universitätsklinikum Heidelberg · MSL Dr. Anna Becker
Insight
Reviewed 16 Apr 2026 by Dr. Sophie Laurent
Action
Medical education program · Dr. Anna Becker · In progress
Decision
Outcome
Closure
Standard response created and approved.